Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy
- 30 September 2004
- journal article
- Published by Elsevier BV in American Journal of Obstetrics and Gynecology
- Vol. 191 (3), 985-992
- https://doi.org/10.1016/j.ajog.2004.05.061
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Maternal toxicity and pregnancy complications in human immunodeficiency virus–infected women receiving antiretroviral therapy: PACTG 316American Journal of Obstetrics and Gynecology, 2004
- The Metropolitan Atlanta Congenital Defects Program: 35 years of birth defects surveillance at the centers for disease control and preventionBirth Defects Research Part A: Clinical and Molecular Teratology, 2003
- Birth defect classification by organ system: a novel approach to heighten teratogenic signalling in a pregnancy registryPharmacoepidemiology and Drug Safety, 2002
- Combination Antiretroviral Strategies for the Treatment of Pregnant HIV-1–Infected Women and Prevention of Perinatal HIV-1 TransmissionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- Is first trimester exposure to the combination of antiretroviral therapy and folate antagonists a risk factor for congenital abnormalities?Sexually Transmitted Infections, 2001
- The relationship of pregnancy to the use of highly active antiretroviral therapyAmerican Journal of Obstetrics and Gynecology, 2001
- Evaluation of selected characteristics of pregnancy drug registriesTeratology, 1999
- Trends in Perinatal Transmission of HIV/AIDS in the United StatesJAMA, 1999